Opening Ceremony at SOLACI-CACI 2017 Congress

The largest Interventional Cardiology Congress in Latin America has already started. At Pacífico Room, Hilton Buenos Aires Hotel, the Scientific and Organizing Committee presented the objectives and contents for the next three intense days of scientific activity.

Opening Ceremony at SOLACI-CACI 2017 Congress
The first Congress activity was an international joint session with TCT.

The first Congress session was an international joint session with TCT.

 

Congress President Dr. Ruben Piraino highlighted the registration record of over 3000 attendees from all over the world. He also mentioned the 450 faculty members (425 from Latin America and 25 international guests) involved in the event and the 10 live cases, the 8 edited cases, round tables, lunch symposiums, and more, as the main attractions in this “unforgettable event.”

 

Dr. Fernando Cura and Dr. Alberto Sampaolesi (from the Scientific Committee) talked about a “need for a different kind of event, given the disparateness within the scientific audience, composed by both novice professionals and true experts in the field.” They also emphasized the crucial support received from the industry, without which no event of this magnitude could have been pulled off. Furthermore, they expressed their hope that “this work will result in growth for this specialty in this geographical region, higher benefits for patients, and, above all, an increase in the quality of cardiovascular health.”

 

SOLACI President Dr. Ricardo Lluberas mentioned that “the work carried out by the Scientific and Organizing Committee throughout this year was absolutely self-sacrificing. In consequence, once this Congress is over and we return to our homes, we will surely bring with us satisfaction derived from the fact that SOLACI-CACI 2017 will have effectively contributed to the strengthening of interventional cardiology in Latin America.”


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...